U.S. markets closed

Syros Pharmaceuticals, Inc. (SYRS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.74-0.15 (-2.55%)
At close: 4:00PM EDT
5.74 0.00 (0.00%)
After hours: 04:33PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close5.89
Bid5.74 x 4000
Ask5.87 x 4000
Day's Range5.69 - 5.92
52 Week Range4.75 - 15.65
Avg. Volume1,297,337
Market Cap355.067M
Beta (5Y Monthly)1.80
PE Ratio (TTM)N/A
EPS (TTM)-1.61
Earnings DateAug 04, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.57
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Syros Pharmaceuticals to Present at JMP Securities 2021 Life Sciences Conference
    Business Wire

    Syros Pharmaceuticals to Present at JMP Securities 2021 Life Sciences Conference

    Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Securities 2021 Life Sciences Conference. Details are as follows:

  • 7 Best Penny Stocks to Buy for Your June Buy List

    7 Best Penny Stocks to Buy for Your June Buy List

    You don’t need a financial expert or anyone of any credentials to tell you why penny stocks are so appealing. That’s akin to explaining how the dazzling lights and sounds of Las Vegas might lure in tourists from out of town. It’s patently obvious. These speculative names are priced cheaply (on paper) and offer the potential of astounding gains. Of course, most money advisors will recommend you stay away from penny stocks. I’m not a financial advisor and most importantly, I’m not your financial a

  • TheStreet.com

    Syros Pharma Skyrockets on Oppenheimer Buy Rating

    Syros Pharmaceuticals jumped after an Oppenheimer analyst assigned a buy rating to the biopharma . Analyst Mark Breidenbach, who also has a share price target of $13,on the stock, said the company hosted a webinar on the treatment for high-risk Myelodysplastic Syndrome (HR-MDS). Myelodysplastic Syndrome is a group of diseases that affect the blood and bone marrow.